CALD Gene Therapy Granted Breakthrough Therapy Designation – Rare Disease Report
Rare Disease Report |
CALD Gene Therapy Granted Breakthrough Therapy Designation
Rare Disease Report Supported by positive data from an ongoing Phase 2/3 study, bluebird bio’s Lenti-D has been granted Breakthrough Therapy designation by the US Food and Drug Administration (FDA) for the treatment of patients with cerebral adrenoleukodystrophy (CALD), … |
|
Cesca Therapeutics’ Chief Technology Officer, Phil Coelho, Provides Deep Dive into the CAR–T Manufacturing Process …
GlobeNewswire (press release) RANCHO CORDOVA, Calif., May 23, 2018 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc. (“Cesca” or the “Company”) (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced … |
|
Cesca Therapeutics’ Chief Technology Officer, Phil Coelho, Provides Deep Dive into the CAR–T Manufacturing Process …
GlobeNewswire (press release) RANCHO CORDOVA, Calif., May 23, 2018 (GLOBE NEWSWIRE) — Cesca Therapeutics Inc. (“Cesca” or the “Company”) (NASDAQ:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced … |
|
Cesca Therapeutics’ Chief Technology Officer, Phil Coelho, Provides Deep Dive into the CAR–T Manufacturing Process …
Nasdaq Cesca Therapeutics Inc. (the “Company”) develops, commercializes and markets a range of automated technologies for CAR–T and other cell-based therapies. Its device division, ThermoGenesis Corp., provides a full suite of solutions for automated clinical … |